Orciprenaline is a beta-2 adrenergic agonist used to treat bronchospasm, asthma, and COPD. A medication used to treat lung conditions including asthma.
- Mechanism
- Curator reviewed
Orciprenaline stimulates the β2-adrenergic receptor expressed in the lungs, uterus, and vasculature supplying skeletal muscles by acting as a moderately selective agonist. It exerts minimal or no effect on alpha-adrenergic receptors. Intracellularly, the actions of orciprenaline are mediated by cAMP, the production of which is augmented by beta stimulation. The drug is believed to work by activating adenylate cyclase, the enzyme responsible for producing the cellular mediator cAMP.
- Primary indication
- For the treatment of bronchospasm, chronic bronchitis, asthma, and emphysema.Curator reviewed · 4 structured indications
- Formula / weight
- C11H17NO3 · 211.2576 g/mol (avg)
- First approval
- Canada, 2002 · United States, 1973
- Also known as
- Metaproterenol · Metaproterenol polistirex
Resolves to
LMOINURANNBYCM-UHFFFAOYSA-NSMILESCC(C)NCC(O)C1=CC(O)=CC(O)=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Orciprenaline, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account